Patients with type 2 diabetes not achieving glycemic targets on OADs with/without basal insulin can reach HbA1c targets with biphasic insulin aspart 30/70

被引：0
|
作者：
Jain, R
Braceras, R
Wahl, T
Wahlen, J
Bressler, P
Deng, L
Garber, A
机构：
[1] Milwaukee Med Clin, Milwaukee, WI USA
[2] Novo Nordisk Inc, Clin Dev Regulatory & Med Affairs, Princeton, NJ USA
[3] Internal Med Associates, Omaha, NE USA
[4] Endocrine Res Specialists, Ogden, UT USA
[5] Endocrine & Diabet Associates, Dallas, TX USA
[6] Baylor Coll Med, Houston, TX 77030 USA
来源：
DIABETOLOGIA | 2005年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
837
引用
收藏
页码：A304 / A304
页数：1
相关论文
共 50 条
  • [21] Longitudinal change in HbA1c in patients with type 2 diabetes: comparison of short-acting, biphasic and basal insulin
    Rose, B.
    [J]. DIABETOLOGE, 2009, 5 (05): : 360 - 360
  • [22] Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes
    Hermansen, K
    Colombo, M
    Storgaard, H
    Ostergaard, A
    Kolendorf, K
    Madsbad, S
    [J]. DIABETES CARE, 2002, 25 (05) : 883 - 888
  • [23] Over 75% of patients with type 2 diabetes reached HbA1c <7% by adding biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment
    Raskin, P.
    Braceras, R.
    Schwartz, S.
    Chaykin, L.
    Chu, P. -L.
    Wynne, A.
    [J]. DIABETOLOGIA, 2006, 49 : 487 - 487
  • [24] Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009–2020
    Emily R. Hankosky
    David Schapiro
    Karli B. Gunn
    Elizabeth B. Lubelczyk
    Jessica Mitroi
    David R. Nelson
    [J]. Diabetes Therapy, 2023, 14 : 967 - 975
  • [25] Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
    Kilo, C
    Mezitis, N
    Jain, R
    Mersey, J
    McGill, J
    Raskin, P
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (06) : 307 - 313
  • [26] IDegAsp lowers the rate of hypoglycaemia vs biphasic insulin aspart 30 in adults with type 2 diabetes achieving glycaemic target (HbA1c <7.0%): a meta-analysis
    Vaag, A.
    Christiansen, J. S.
    Niskanen, L.
    Johansen, T.
    Rasmussen, S.
    Fulcher, G.
    [J]. DIABETOLOGIA, 2014, 57 : S400 - S400
  • [27] Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA
    Billings, L. K.
    Mocarski, M.
    Basse, A.
    Hunt, B.
    Valentine, W. J.
    Jodar, E.
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 271 - 282
  • [28] IMPROVE (TM) observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus
    Kawamori, Ryuzo
    Valensi, Paul
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 507 - 516
  • [29] Transferring patients with type 2 diabetes no longer controlled with basal human insulin to biphasic insulin aspart 30 leads to improved control
    Barbonta, Diana H.
    Mocan, Emiliana
    Yeo, Jing Ping
    [J]. DIABETES, 2008, 57 : A562 - A563
  • [30] Predictors of worsening of glycemic control in patients with type 2 diabetes mellitus not on insulin and with HbA1c≤ 7.0%
    De Valk, HW
    Van Dillen, MEL
    Chorus, RCH
    De Bruin, HJ
    Erkelens, DW
    [J]. DIABETES, 2001, 50 : A109 - A110
12345